Bending the asthma cost curve: Is optimizing medication the answer?

项目总结/摘要 减少哮喘药物治疗是一种慢性疾病管理策略， 限制潜在的副作用，减轻治疗负担，降低成本。我们 初步研究结果表明，我们可能没有对一些人进行足够的治疗， 哮喘药物和治疗他人超过他们的需要。我们假设 哮喘稳定的个体停止哮喘药物治疗后， 哮喘的结果和减少的总医疗费用相比， 不要停止哮喘药物治疗。我们将使用个人参与国家 代表性医疗支出专门小组调查，比较1年基线哮喘 药物分配，哮喘急性发作率和医疗支出， 在同一个人的第二年。了解哪些策略有效 对于节省资金和保持良好的临床结果非常重要， 哮喘患者经历了与哮喘相关的费用增加， 管理他们的疾病。

PROJECT SUMMARY/ABSTRACT Stepping down asthma medications is a chronic disease management strategy that may limit potential side effects, reduce treatment burden, and decrease costs. Our preliminary findings suggest that we may not be treating some individuals with enough asthma medications and treating others with more than they need. We hypothesize that individuals with stable asthma who step down their asthma medications will have similar asthma outcomes and decreased total medical expenditures compared to those that do not step down asthma medication. We will use individuals participating in the nationally representative Medical Expenditure Panel Survey to compare 1 year baseline asthma medication dispensing, asthma exacerbation rates, and medical expenditures to the subsequent year in the same individuals. Understanding which strategies are effective for saving money and maintaining favorable clinical outcomes is important for individuals with asthma who have experienced increasing costs associated with managing their disease.